Fenimore Asset Management Inc. trimmed its stake in Checkpoint Therapeutics Inc (NASDAQ:CKPT) by 46.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 32,400 shares of the company’s stock after selling 27,600 shares during the period. Fenimore Asset Management Inc. owned about 0.09% of Checkpoint Therapeutics worth $98,000 as of its most recent filing with the SEC.
Separately, Bank of New York Mellon Corp purchased a new stake in shares of Checkpoint Therapeutics in the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 8.35% of the company’s stock.
CKPT has been the topic of a number of research analyst reports. Lake Street Capital initiated coverage on shares of Checkpoint Therapeutics in a research note on Wednesday, May 29th. They issued a “buy” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Checkpoint Therapeutics in a research note on Friday, August 9th. Finally, ValuEngine raised shares of Checkpoint Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
Checkpoint Therapeutics (NASDAQ:CKPT) last announced its earnings results on Thursday, August 8th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. Checkpoint Therapeutics had a negative net margin of 712.89% and a negative return on equity of 263.14%. The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $0.96 million. As a group, research analysts predict that Checkpoint Therapeutics Inc will post -0.65 earnings per share for the current year.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers.
Recommended Story: What is an inverted yield curve?
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.